Gladstone Investigators and Xyphos Partner to Successfully Adapt CAR-T Immunotherapy to Target the HIV Latent Reservoir
Gladstone Investigators and Xyphos Partner to Successfully Adapt CAR-T Immunotherapy to Target the HIV Latent Reservoir
Gladstone Institutes and Xyphos Biosciences have shown that a cell-based immunotherapy, convertibleCAR®, can reduce the latent reservoir of virus in HIV-infected patients on anti-retroviral therapy
News Release HIV/AIDS Greene Lab